Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge.
Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge.
复制标题
DOI：
10.3390/vaccines9080881
复制
发表时间：
2021-08-09
期刊：
影响因子：
7.8
通讯作者：
Roberts MS
中科院分区：
文献类型：
--
作者：
King RG;Silva-Sanchez A;Peel JN;Botta D;Dickson AM;Pinto AK;Meza-Perez S;Allie SR;Schultz MD;Liu M;Bradley JE;Qiu S;Yang G;Zhou F;Zumaquero E;Simpler TS;Mousseau B;Killian JT Jr;Dean B;Shang Q;Tipper JL;Risley CA;Harrod KS;Feng T;Lee Y;Shiberu B;Krishnan V;Peguillet I;Zhang J;Green TJ;Randall TD;Suschak JJ;Georges B;Brien JD;Lund FE;Roberts MS
2019冠状病毒病（COVID-19）大流行凸显了有效预防接种疫苗的迫切需要，以防止严重急性呼吸系统综合征冠状病毒2（SARS-CoV-2）的传播。鼻内疫苗接种是预防COVID-19的一种有吸引力的策略，因为鼻粘膜是SARS-CoV-2进入的一线屏障。目前的肌内疫苗引起全身免疫，但不一定是高水平的粘膜免疫。在这里，我们在近交系、远交系和转基因小鼠中测试了单次鼻内剂量的我们的候选5型腺病毒载体疫苗，该疫苗编码SARS-CoV-2刺突蛋白（AdCOVID）的受体结合结构域（RBD）。AdCOVID单次鼻内接种通过诱导呼吸道粘膜伊加、血清中和抗体以及具有Th 1样细胞因子表达谱的CD 4+和CD 8 + T细胞，引发了针对RBD的强烈和集中的免疫应答。一剂AdCOVID疫苗可使免疫力持续6个月以上。此外，单次鼻内给药完全保护K18-hACE 2小鼠免受致死性SARS-CoV-2攻击，防止体重减轻和死亡。这些数据表明，AdCOVID促进伴随的全身和粘膜免疫，代表了一种有希望的候选疫苗。
The coronavirus disease 2019 (COVID-19) pandemic has highlighted the urgent need for effective prophylactic vaccination to prevent the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Intranasal vaccination is an attractive strategy to prevent COVID-19 as the nasal mucosa represents the first-line barrier to SARS-CoV-2 entry. The current intramuscular vaccines elicit systemic immunity but not necessarily high-level mucosal immunity. Here, we tested a single intranasal dose of our candidate adenovirus type 5-vectored vaccine encoding the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein (AdCOVID) in inbred, outbred, and transgenic mice. A single intranasal vaccination with AdCOVID elicited a strong and focused immune response against RBD through the induction of mucosal IgA in the respiratory tract, serum neutralizing antibodies, and CD4+ and CD8+ T cells with a Th1-like cytokine expression profile. A single AdCOVID dose resulted in immunity that was sustained for over six months. Moreover, a single intranasal dose completely protected K18-hACE2 mice from lethal SARS-CoV-2 challenge, preventing weight loss and mortality. These data show that AdCOVID promotes concomitant systemic and mucosal immunity and represents a promising vaccine candidate.
登录
查看更多内容
影响因子：
64.5
作者：
Hou, Yixuan J.;Okuda, Kenichi;Baric, Ralph S.
通讯作者：
Baric, Ralph S.
DOI：
10.4049/jimmunol.1601775
发表时间：
2017-07-01
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Boyaka PN
通讯作者：
Boyaka PN
影响因子：
13.6
作者：
通讯作者：
--
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
DOI：
10.1007/s40292-021-00454-w
发表时间：
2021-07
期刊：
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension
影响因子：
--
作者：
Boari GEM;Bonetti S;Braglia-Orlandini F;Chiarini G;Faustini C;Bianco G;Santagiuliana M;Guarinoni V;Saottini M;Viola S;Ferrari-Toninelli G;Pasini G;Bonzi B;Desenzani P;Tusi C;Malerba P;Zanotti E;Turini D;Rizzoni D
通讯作者：
Rizzoni D